Related Experiment Videos
ICRF-159 in advanced gastric cancer. Absence of activity
Abstract:
ICRF-159, and EDTA derivative antitumor agent, was given to 21 patients with advanced gastric cancer in a weekly dose of 3000 mg/m2. Of the 21 patients, 11 had failed prior drug therapies and 10 were previously untreated. No patient achieved an objective partial response (actual response less than 15% with 95% confidence level). One previously treated patient had a minor response lasting 12 weeks and four patients (three previously untreated) had stable disease lasting 4-8 weeks. Toxicity was acceptable, consisting of mild nausea and moderate myelosuppression. Median survival after treatment was 17.5 weeks in previously untreated patients and 9 weeks in previously treated patients. We conclude that ICRF-159 is inactive in advanced gastric cancer when given on a weekly schedule.
Insights
The antitumor agent ICRF-159 showed no significant effectiveness in treating advanced gastric cancer. This study found ICRF-159 inactive in gastric cancer patients on a weekly schedule.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced gastric cancer presents a significant treatment challenge.
- Novel therapeutic agents are continuously investigated for gastric cancer.
- ICRF-159 is an EDTA derivative with known antitumor properties.
Purpose of the Study:
- To evaluate the efficacy and toxicity of ICRF-159 in patients with advanced gastric cancer.
- To determine the response rate and survival outcomes of ICRF-159 treatment.
Main Methods:
- A total of 21 patients with advanced gastric cancer were enrolled.
- Patients received ICRF-159 at a weekly dose of 3000 mg/m2.
- The study included both previously treated and untreated patients.
Main Results:
- No objective partial responses were observed in any patient.
- One patient achieved a minor response, and four patients had stable disease.
- Toxicity was generally mild, with nausea and myelosuppression being the main concerns.
- Median survival was 17.5 weeks for untreated and 9 weeks for treated patients.
Conclusions:
- ICRF-159 demonstrates inactivity against advanced gastric cancer when administered weekly.
- The agent's efficacy does not support its use in this patient population and schedule.
- Further investigation into ICRF-159 may require different dosing or patient selection criteria.